Berzaczy, D.; Haug, A.; Staber, P.B.; Raderer, M.; Kiesewetter, B.; Jaeger, U.; Kornauth, C.; Simonitsch-Klupp, I.; Mayerhoefer, M.E.
RECIL Versus Lugano for Treatment Response Assessment in FDG-Avid Non-Hodgkin Lymphomas: A Head-to-Head Comparison in 54 Patients. Cancers 2020, 12, 9.
https://doi.org/10.3390/cancers12010009
AMA Style
Berzaczy D, Haug A, Staber PB, Raderer M, Kiesewetter B, Jaeger U, Kornauth C, Simonitsch-Klupp I, Mayerhoefer ME.
RECIL Versus Lugano for Treatment Response Assessment in FDG-Avid Non-Hodgkin Lymphomas: A Head-to-Head Comparison in 54 Patients. Cancers. 2020; 12(1):9.
https://doi.org/10.3390/cancers12010009
Chicago/Turabian Style
Berzaczy, Dominik, Alexander Haug, Philipp B. Staber, Markus Raderer, Barbara Kiesewetter, Ulrich Jaeger, Christoph Kornauth, Ingrid Simonitsch-Klupp, and Marius E. Mayerhoefer.
2020. "RECIL Versus Lugano for Treatment Response Assessment in FDG-Avid Non-Hodgkin Lymphomas: A Head-to-Head Comparison in 54 Patients" Cancers 12, no. 1: 9.
https://doi.org/10.3390/cancers12010009
APA Style
Berzaczy, D., Haug, A., Staber, P. B., Raderer, M., Kiesewetter, B., Jaeger, U., Kornauth, C., Simonitsch-Klupp, I., & Mayerhoefer, M. E.
(2020). RECIL Versus Lugano for Treatment Response Assessment in FDG-Avid Non-Hodgkin Lymphomas: A Head-to-Head Comparison in 54 Patients. Cancers, 12(1), 9.
https://doi.org/10.3390/cancers12010009